Probleme beim Einloggen

Onco'Zine - The International Cancer Network

Onco’Zine is raising awareness of the impact of cancer, cancer diagnosis and treatment an publishes a broad range of topics and timely news.

Peter Hofland
In this edition of The OncoZine Brief Peter Hofland talks with Charlie Johnson, Chief Executive Officer of ADC Bio, a biotechnology company specialized in the development of Antibody-drug Conjugates. This Interview was recorded during the annual pharmaceutical industry meeting, CPhI Worldwide, held October 9 – 11, 2018 in Madrid, Spain. This edition was a co-production with ADC Review | the Journal of Antibody-drug Conjugates - and Onco’Zine -
Dieser Beitrag kann nicht mehr kommentiert werden.
Rakesh Goyal Growing Adoption of Immunotherapy over other treatment options drives the global cancer immunotherapy market
Immunotherapy is one of the most recent approaches for cancer therapy. It is a treatment that uses body’s own immune system to help fight cancer. It is widely used in hospital settings and clinics for the treatment of different types of cancers such as lung cancer, breast cancer, colorectal cancer, multiple myeloma, melanoma, prostate cancer, and other types of cancer. “Meticulous Research” in its latest publication states that, “the global Cancer Immunotherapy Market is will reach $152,829.0 million by 2024, growing at a CAGR of 13.8% during the forecast period of 2018 to 2024.”
This growth is primarily driven by the rising incidence of cancer globally, increasing survival rate in the patients adopting cancer immunotherapy as a treatment option, growing adoption of cancer immunotherapies over other cancer treatment options, and rising number of technology collaborations and mergers in the market.
according to the study (long-term survival rate in patients with metastatic NSCLC treated with an immune checkpoint inhibitor) presented at the American Association for Cancer Research (AACR) in 2017, 16% of patients with advanced NSCLC treated with Nivolumab were alive 5 years after treatment; compares with only about 4% of patients alive at 5 years with conventional chemotherapy. This increase in adoption of the immunotherapies due to its advantages over the traditional therapies and longer-term survival rate is expected to drive the overall cancer immunotherapy market during the forecast period.
The report provides meticulous analysis of cancer immunotherapy market by segmenting it on the basis of type (monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, cell therapy), application (lung, breast, multiple myeloma, colorectal, melanoma, prostate), and end user (hospitals, clinics & others).
Key Topics Covered in This Report:
Research Methodology
Executive Summary
Market Share Analysis
Market Insights
Cancer Immunotherapy Market, By Type
Cancer Immunotherapy Market, By Application
Cancer Immunotherapy Market, By End User
Geographic Analysis
Competitive Landscape
Company Profiles
To browse sample research report@
Akshay Singhania Digital Pathology market growth, share, demand and analysis of key players - research forecasts to 2025
The digital pathology market is estimated to grow at a CAGR of 12.5% during the forecast period from 2018 to 2025. The market for digital pathology is projected to reach US$ 992.14 Mn in 2025.
Get PDF sample Copy@
The List of Companies
2. Apollo Enterprise Imaging Corp.
3. Huron Digital Pathology
4. Leica Biosystems Nussloch GmbH
5. Hamamatsu Photonics K.K.
6. XIFIN, Inc.
7. Ventana Medical Systems, Inc.
8. Koninklijke Philips N.V.
9. Visiopharm
10. Indica Labs, Inc.
Advancement in the equipment, teleconsultation & ease of transportation, rising prevalence of cancer, and increasing number of conferences & meetings to create awareness are the major factors primarily attributed to the growth of the market. Additionally, major players in this market are involved in research and development activities. These players have been upgrading their product portfolio by applying for approvals as well as launching new products. For instance, in July 2017, The 3D Histech launched the windows 10 compatible TMA control 2.7 SW, which can be applied for the complete tissue microarray (TMA) products. This update was aimed to aid in placing different samples into one paraffin block. In addition, it was also designed to save time & costs of tissue preparation, staining and slide preparation.
Dhanashri Gore Comprehensive analysis on Precision Medicine Market With Key Players
Request Sample Copy of this Report :
Prominent Players:
Some of the major players of global precision medicine market are Intomics, F. Hoffmann-La Roche, NanoString Technologies, Laboratory Corporation of America Holdings, Biocrates Life Sciences, Teva Pharmaceutical, Tepnel Pharma Services, Novartis, Silicon Biosystems, Quest Diagnostics and Ferrer InCode. Increased focus on R&D investment for developing innovative software tools to integrate health data for treatment of chronic ailments is the major strategy adopted by these players to maintain market foothold.
Growth drivers :
-Advancement in cancer biology
-Rise in the online collaborative forums
-Increased adoption of gene therapy
-Advancements in big data analytics
Precision Medicine Market, By Technology :
Drug discovery accounted for largest market share in 2016 and is anticipated to grow at approximately 8.3% CAGR over the forecast period. Advancements in pharmacogenomics which allows to predict the efficacy of a drug using genetic information of individuals will pave the way for drug development. Furthermore, development of drug focused on specific targets such as Kalydeco used in the treatment of cystic fibrosis which targets causal G551D gene mutations will favour segment growth.
Big data analytics market size will witness robust growth over the forecast timeframe. Rising usage of electronic health records, development of various big data platforms utilising genetic information of patients along with increasing efforts of collaborative forums launching events and initiatives will boost the global precision medicine market growth in the future.
Precision Medicine Market, By Application :
Oncology segment held the largest revenue share in 2016 and should show a similar trend in the future. Rising prevalence of cancer globally along with the development of targeted therapies for cancer patients based on their genetic factors over conventional chemotherapy will spur market size. Increasing focus on precision oncology with investment of USD 70 million by NIH will further accelerate market growth.
Respiratory segment will also witness significant growth in the future. Lifestyle factors such as smoking leads to elevated risk of developing chronic obstructive pulmonary disease (COPD) which further escalates the need to develop novel biomarkers, increase the efficiency of indicators, phenotypes and select effective treatment options facilitating precision medicine.


Infos zu den Moderatoren

Über die Gruppe "Onco'Zine - The International Cancer Network"

  • Gegründet: 17.01.2011
  • Mitglieder: 27
  • Sichtbarkeit: offen
  • Beiträge: 21
  • Kommentare: 0